Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ORXOY | OTC Markets | USD | Delayed | |
ORX | Stockholm | SEK | Real-time |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Name | Age | Since | Title |
---|---|---|---|
James Julian Noble | 64 | 2020 | Independent Chairman of the Board |
Staffan Lindstrand | 62 | 2002 | Independent Director |
George Frederick Wilkinson | 68 | 2019 | Independent Director |
Christine Rankin | 60 | 2022 | Independent Director |
Robin Evers | 54 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review